Iboctadekin

DB14920InvestigationalProtein Based Therapies

Iboctadekin is under investigation in clinical trial NCT00500058 (A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18).

Mechanism: Pharmacologically active on Interleukin-18 receptor 1
Curator reviewed
Code names: SB-485232

Resolves to

Compound

UNIIX08H9UZ7TOCAS479198-61-3

Targets

Q13478IL18R1

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Iboctadekin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account